FDA Approves Doravirine/Islatravir Two-Drug Regimen for HIV-1
Overview
The FDA has approved the once-daily oral combination doravirine/islatravir (DOR/ISL) for adults with virologically suppressed HIV-1, based on Phase 3 trials demonstrating noninferior efficacy and comparable safety to standard antiretroviral therapy. This two-drug, tenofovir-free regimen offers a simplified treatment option for patients without prior treatment failure or resistance.
Background
Current HIV treatment often involves multi-drug regimens to maintain viral suppression. Doravirine/islatravir is a novel two-drug combination that does not include an integrase strand transfer inhibitor and is tenofovir-free. Islatravir acts as a nucleoside analog inhibiting viral replication through multiple mechanisms, including reverse transcriptase interference. Simplified regimens like DOR/ISL may benefit patients with comorbidities or those seeking to reduce medication burden.
Data Highlights
Trial
Comparator
Viral Suppression at Week 48 (%)
MK-8591A-052
Bictegravir/emtricitabine/tenofovir alafenamide
DOR/ISL: 92% vs Comparator: 94%
Key Findings
DOR/ISL demonstrated noninferior efficacy to standard three-drug regimens in adults with suppressed HIV-1 at 48 weeks.
Approximately 92% of patients on DOR/ISL maintained viral suppression (HIV-1 RNA <50 copies/mL) at 48 weeks, comparable to 94% on standard therapy.
Long-term data up to 96 weeks showed sustained viral suppression and stable safety profiles with low discontinuation rates.
DOR/ISL is tenofovir-free and does not contain an integrase strand transfer inhibitor, providing an alternative for patients with specific treatment needs.
The regimen is contraindicated with strong CYP3A inducers and with lamivudine or emtricitabine due to potential drug interactions and reduced efficacy.
Clinical Implications
Doravirine/islatravir offers a simplified, effective two-drug regimen for virologically suppressed adults without prior treatment failure, potentially improving adherence and tolerability. Its unique profile makes it suitable for patients with comorbidities or those seeking to minimize drug exposure. Clinicians should avoid coadministration with contraindicated agents to maintain efficacy.
Conclusion
The FDA approval of doravirine/islatravir provides a validated, simplified treatment option for maintaining viral suppression in adults with HIV-1, expanding individualized therapy choices. Continued monitoring will further define its role in long-term HIV management.
Related Resources & Content
Merk, Merk -- Two-Drug HIV Regimen Gains FDA Approval
